22 Sep 2022 |
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr
|
21 Sep 2022 |
Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor
|
21 Sep 2022 |
Sesen Bio and Carisma Therapeutics Announce Merger Agreement
|
21 Sep 2022 |
Octagon Therapeutics Enters Inflammation-Focused Research Alliance with Novo Nordisk
|
21 Sep 2022 |
Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy
|
20 Sep 2022 |
Versantis to be acquired by GENFIT, combining forces to continue the development of its revolutionary therapeutics for patients with liver diseases
|
16 Sep 2022 |
Integral Molecular Licenses Claudin 18.2 Monoclonal Antibodies to CARTEXELL for Oncology Cell Therapies
|
13 Sep 2022 |
Novo Nordisk and Microsoft collaborate to accelerate drug discovery and development using big data and artificial intelligence
|
09 Sep 2022 |
Photys Therapeutics Debuts with $75 Million Series A Funding to Advance New Class of Bifunctional Molecules for Precision Phosphorylation to Modulate and Repair Disease-Driving Proteins
|
07 Sep 2022 |
Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche
|
07 Sep 2022 |
Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines
|
06 Sep 2022 |
PhoreMost enters multi-project drug target discovery collaboration with Roche
|
01 Sep 2022 |
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
|
23 Aug 2022 |
NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)
|
17 Aug 2022 |
Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery
|
16 Aug 2022 |
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
|
11 Aug 2022 |
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
|
11 Aug 2022 |
GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases
|
10 Aug 2022 |
Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease
|
08 Aug 2022 |
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
|
05 Aug 2022 |
Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China
|
05 Aug 2022 |
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
|
05 Aug 2022 |
Gilead Sciences to acquire MiroBio
|
05 Aug 2022 |
Amgen to acquire Chemocentryx for $4 billion in cash
|
04 Aug 2022 |
Radiopharm enters into strategic collaboration with Lantheus and assumes PD-L1 licensing agreement from Nanomab
|